Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:barrelLength |
high_affinity_for_HSP90
|
| gptkbp:chemicalFormula |
C18H20N2O3S
thiazole derivative |
| gptkbp:clinicalTrials |
gptkb:United_States
Europe Phase 2 |
| gptkbp:collaborations |
collaborated with academic institutions
collaborated with research organizations |
| gptkbp:composedOf |
chemical synthesis
multi-step synthesis |
| gptkbp:developedBy |
gptkb:Synta_Pharmaceuticals
|
| gptkbp:dissolved |
soluble in DMSO
soluble in ethanol slightly soluble in water |
| gptkbp:enginePower |
7.4
|
| gptkbp:financial_aid |
stable under normal conditions
|
| https://www.w3.org/2000/01/rdf-schema#label |
elesclomol
|
| gptkbp:isATypeOf |
100507-64-1
|
| gptkbp:isPortrayedBy |
2010
|
| gptkbp:marketSegment |
not marketed
|
| gptkbp:number_of_stages |
tolerated at high doses
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
discontinued
|
| gptkbp:regulatoryCompliance |
not_approved_by_FDA
|
| gptkbp:researchAndDevelopment |
further studies needed
|
| gptkbp:researchFocus |
cancer therapy
oxidative stress modulation HSP90_inhibition |
| gptkbp:resolution |
promising efficacy in melanoma
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
underwent safety assessments
|
| gptkbp:sideEffect |
anemia
fatigue nausea rash hypokalemia |
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
cancer
mitochondrial function |
| gptkbp:team |
3.5
|
| gptkbp:triggerType |
induces oxidative stress in cancer cells
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:weight |
332.43 g/mol
|